Veeva Systems Celebrates Milestone as Indero Launches 40th RTSM Study

On March 19, 2025, Veeva Systems Inc. (NYSE: VEEV) announced a significant milestone in its collaboration with Indero, formerly known as Innovaderm Research. Indero has successfully launched its 40th Randomization and Trial Supply Management (RTSM) study utilizing Veeva's advanced RTSM platform. This achievement underscores the continued partnership between the two organizations and highlights the effectiveness of Veeva's technology in enhancing clinical trial operations.

Indero's decision to standardize its operations with Veeva RTSM has led to remarkable improvements in its clinical trial processes. The integration of Veeva's advanced capabilities has not only driven efficiency but also fostered greater process consistency and streamlined execution. Eric Hardy, Indero's senior director of biometrics, emphasized the benefits of this collaboration, stating, "As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution."

The ability to accelerate the development and delivery of therapies is crucial in the highly competitive biopharmaceutical landscape. Hardy noted that the enhanced speed and effectiveness provided by Veeva RTSM allow Indero to bring therapies to market faster, benefiting sponsors, sites, and patients alike.

The launch of the 40th RTSM study represents more than just a numerical milestone; it reflects the ongoing commitment between Veeva and Indero to refine and standardize clinical processes. Since adopting Veeva RTSM, Indero has worked closely with Veeva to implement best practices that contribute to the long-term success of its clinical trials.

Steve Simmerman, general manager of Veeva RTSM, commented on the partnership's impact, stating, "With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies." This collaboration exemplifies how standardized clinical processes can speed up study timelines and advance the entire industry.

As a leader in cloud software for the life sciences sector, Veeva Systems is dedicated to innovation and customer success. The company serves over 1,000 clients, including some of the largest biopharmaceutical companies and emerging biotech firms. Veeva operates as a Public Benefit Corporation, balancing the interests of various stakeholders, including customers, employees, and shareholders.

For those interested in learning more about Veeva's enterprise standard RTSM, additional information can be found on their official website.

The successful launch of Indero's 40th RTSM study is a testament to the power of strategic partnerships in the life sciences sector. Veeva Systems continues to play a pivotal role in enhancing clinical trial efficiency and effectiveness, ultimately contributing to faster market access for vital therapies. As the industry evolves, collaborations like this will be crucial in driving innovation and improving patient outcomes.